bosutinib 100 MG Oral Tablet
- RxCUI
- 1307624
- RxNorm name
- bosutinib 100 MG Oral Tablet
- Display name
- Bosutinib (Oral Pill)
- Full name
- bosutinib 100 MG Oral Tablet
- Term type
- SCD
- Status
- Active
- Strength
- 100 mg
- Dose form
- Tab
- Route
- Oral Pill
- Updated
- 2026-07-22 07:08:46
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 102012
- Active start
- 102012
- Multiple ingredient
- NO
- Branded
- NO
Ingredients And Strength#
| Ingredient | Strength | Base | Basis of strength |
|---|---|---|---|
| bosutinib | 100 MG / 1 EACH | bosutinib | bosutinib |
Dose Form Concepts#
| Dose form | RxCUI |
|---|---|
| Oral Tablet | 317541 |
Derived Ingredient Concepts#
| Ingredient | RxCUI |
|---|---|
| bosutinib | 1307619 |
Source Vocabulary Codes#
| Code type | Value | Category |
|---|---|---|
| PRESCRIBABLE | Y | ATTRIBUTES |
| RXNAV_STR | bosutinib 100 MG Oral Tablet | NAMES |
| RxNorm Name | bosutinib 100 MG Oral Tablet | NAMES |
| RxNorm Synonym | bosutinib 100 MG (as bosutinib monohydrate 103.4 MG) Oral Tablet | NAMES |
| TTY | SCD | ATTRIBUTES |
| SPL_SET_ID | 2ea1617f-41d3-479a-87d5-177013d39193 | CODES |
| SPL_SET_ID | 8f3e9739-8ec1-4ea9-b1bc-185fd07d84e4 | CODES |
| RxCUI | 1307624 | CODES |
| MMSL_CODE | CD27854 | CODES |
FDA NDC Products And Packages#
| Package NDC | Product NDC | Name | Labeler | Application |
|---|---|---|---|---|
| 46708-311-35 | 46708-311 | Bosutinib Bosutinib | Alembic Pharmaceuticals Limited | ANDA209543 |
| 62332-311-35 | 62332-311 | Bosutinib Bosutinib | Alembic Pharmaceuticals Inc. | ANDA209543 |
Drugs@FDA Applications#
| Application | NDC | Name | Marketing category | Labeler |
|---|---|---|---|---|
| ANDA209543 | 46708-311 | Bosutinib Bosutinib | ANDA | Alembic Pharmaceuticals Limited |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| adc84ad5-a04d-4fee-9ba8-91f7abd928e3 | bosutinib 100 MG Oral Tablet | PSN | 32 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | 20260310 |
| adc84ad5-a04d-4fee-9ba8-91f7abd928e3 | bosutinib 100 MG Oral Tablet | SCD | 32 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | 20260310 |
| adc84ad5-a04d-4fee-9ba8-91f7abd928e3 | bosutinib 100 MG (as bosutinib monohydrate 103.4 MG) Oral Tablet | SY | 32 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | 20260310 |
| 2ea1617f-41d3-479a-87d5-177013d39193 | bosutinib 100 MG Oral Tablet | SCD | 20 | These highlights do not include all the information needed to use BOSUTINIB TABLETS safely and effectively. See full prescribing information for BOSUTINIB TABLETS. BOSUTINIB tablets, for oral use Initial U.S. Approval: 2012 | 20260520 |
| 2ea1617f-41d3-479a-87d5-177013d39193 | bosutinib 100 MG (as bosutinib monohydrate 103.4 MG) Oral Tablet | SY | 20 | These highlights do not include all the information needed to use BOSUTINIB TABLETS safely and effectively. See full prescribing information for BOSUTINIB TABLETS. BOSUTINIB tablets, for oral use Initial U.S. Approval: 2012 | 20260520 |
| 2ea1617f-41d3-479a-87d5-177013d39193 | bosutinib 100 MG Oral Tablet | PSN | 20 | These highlights do not include all the information needed to use BOSUTINIB TABLETS safely and effectively. See full prescribing information for BOSUTINIB TABLETS. BOSUTINIB tablets, for oral use Initial U.S. Approval: 2012 | 20260520 |
| d5929f91-6496-4c0e-97e8-0bd524e15763 | bosutinib 100 MG (as bosutinib monohydrate 103.4 MG) Oral Tablet | SY | 6 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | 20260528 |
| d5929f91-6496-4c0e-97e8-0bd524e15763 | bosutinib 100 MG Oral Tablet | PSN | 6 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | 20260528 |
| d5929f91-6496-4c0e-97e8-0bd524e15763 | bosutinib 100 MG Oral Tablet | SCD | 6 | These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF ® (bosutinib) tablets, for oral use BOSULIF ® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012 | 20260528 |
| 8f3e9739-8ec1-4ea9-b1bc-185fd07d84e4 | bosutinib 100 MG Oral Tablet | SCD | 2 | These highlights do not include all the information needed to use BOSUTINIB TABLETS safely and effectively. See full prescribing information for BOSUTINIB TABLETS. BOSUTINIB tablets, for oral use Initial U.S. Approval: 2012 | 20260522 |
| 8f3e9739-8ec1-4ea9-b1bc-185fd07d84e4 | bosutinib 100 MG Oral Tablet | PSN | 2 | These highlights do not include all the information needed to use BOSUTINIB TABLETS safely and effectively. See full prescribing information for BOSUTINIB TABLETS. BOSUTINIB tablets, for oral use Initial U.S. Approval: 2012 | 20260522 |
| 8f3e9739-8ec1-4ea9-b1bc-185fd07d84e4 | bosutinib 100 MG (as bosutinib monohydrate 103.4 MG) Oral Tablet | SY | 2 | These highlights do not include all the information needed to use BOSUTINIB TABLETS safely and effectively. See full prescribing information for BOSUTINIB TABLETS. BOSUTINIB tablets, for oral use Initial U.S. Approval: 2012 | 20260522 |
DailyMed Labels#
| Set ID | Title | Manufacturer | Effective |
|---|---|---|---|
| 8f3e9739-8ec1-4ea9-b1bc-185fd07d84e4 | These highlights do not include all the information needed to use BOSUTINIB TABLETS safely and effectively. See full prescribing information for BOSUTINIB TABLETS. BOSUTINIB tablets, for oral use Initial U.S. Approval: 2012 | Alembic Pharmaceuticals Limited | 20260522 |
| 2ea1617f-41d3-479a-87d5-177013d39193 | These highlights do not include all the information needed to use BOSUTINIB TABLETS safely and effectively. See full prescribing information for BOSUTINIB TABLETS. BOSUTINIB tablets, for oral use Initial U.S. Approval: 2012 | Alembic Pharmaceuticals Inc. | Alembic Pharmaceuticals Limited | 20260520 |
| 2ea1617f-41d3-479a-87d5-177013d39193 | These highlights do not include all the information needed to use BOSUTINIB TABLETS safely and effectively. See full prescribing information for BOSUTINIB TABLETS. BOSUTINIB tablets, for oral use Initial U.S. Approval: 2012 | Alembic Pharmaceuticals Inc. | Alembic Pharmaceuticals Limited | 20260519 |
| 8f3e9739-8ec1-4ea9-b1bc-185fd07d84e4 | These highlights do not include all the information needed to use BOSUTINIB TABLETS safely and effectively. See full prescribing information for BOSUTINIB TABLETS. BOSUTINIB tablets, for oral use Initial U.S. Approval: 2012 | Alembic Pharmaceuticals Limited | 20260519 |
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | L01EA | BCR-ABL tyrosine kinase inhibitors | ATC1-4 | bosutinib | |
| FDASPL | N0000175605 | Kinase Inhibitor | EPC | has_epc | bosutinib |
| FDASPL | N0000020009 | Bcr-Abl Tyrosine Kinase Inhibitors | MOA | has_moa | bosutinib |
| MEDRT | D000814 | Aniline Compounds | CHEM | has_ingredient | bosutinib |
| MEDRT | D009570 | Nitriles | CHEM | has_ingredient | bosutinib |
| MEDRT | D011804 | Quinolines | CHEM | has_ingredient | bosutinib |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | bosutinib |
| MEDRT | D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | DISEASE | may_treat | bosutinib |
| MEDRT | N0000020001 | Tyrosine Kinase Inhibitors | MOA | has_moa | bosutinib |
| MEDRT | N0000175672 | Cellular Proliferation Alteration | PE | has_pe | bosutinib |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | AVAILABLE_STRENGTH | 100 MG |
| ATTRIBUTES | GENERAL_CARDINALITY | SINGLE |
| ATTRIBUTES | HUMAN_DRUG | US |
| ATTRIBUTES | PRESCRIBABLE | Y |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| ATTRIBUTES | SCHEDULE | 0 |
| ATTRIBUTES | TTY | SCD |
| CODES | ANDA | ANDA209543 |
| CODES | MMSL_CODE | CD27854 |
| CODES | RxCUI | 1307624 |
| CODES | SNOMEDCT | 1145410009 |
| CODES | SPL_SET_ID | 2ea1617f-41d3-479a-87d5-177013d39193 |
| CODES | SPL_SET_ID | 8f3e9739-8ec1-4ea9-b1bc-185fd07d84e4 |
| CODES | VUID | 4031694 |
| NAMES | Prescribable Synonym | bosutinib 100 MG Oral Tablet |
| NAMES | RXNAV_STR | bosutinib 100 MG Oral Tablet |
| NAMES | RxNorm Name | bosutinib 100 MG Oral Tablet |
| NAMES | RxNorm Synonym | bosutinib 100 MG (as bosutinib monohydrate 103.4 MG) Oral Tablet |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | Micromedex RED BOOK |
| SOURCES | Source | Multum MediSource Lexicon |
| SOURCES | Source | National Drug Data File Plus Source Vocabulary |
| SOURCES | Source | US Edition of SNOMED_CT |
| SOURCES | Source | Veterans Health Administration National Drug File |